Synergistic Chemo-thermal Therapy of Cancer by DNA-Templated Silver Nanoclusters and Polydopamine Nanoparticles
Source abstract
Abstract
Herein, we develop a novel and effective combination nanoplatform for cancer theranostics. Folic acid (FA) is first modified on the photothermal agent of polydopamine (PDA), which possesses excellent near-infrared (NIR) absorbance and thermal conversion features. Temperature-sensitive silver nanoclusters (AgNCs) are then synthesized on the DNA template that also loads the anticancer drug doxorubicin (Dox). After accumulation in cancer cells, PDA generates cytotoxic heat upon excitation of NIR light for photothermal therapy. On the other hand, the temperature increment is able to destroy the template of AgNCs, leading to the fluorescence variation and controlled release of Dox for chemotherapy. The combined nanosystem exhibits outstanding fluorescence tracing, NIR photothermal transduction, as well as chemo drug delivery capabilities. Both in vitro and in vivo results demonstrate excellent tumor growth suppression phenomena and no apparent adverse effects. This research provides a powerful targeted nanoplatform for cancer theranostics, which may have great potential value for future clinical applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanocluster Synthesis and Applications · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, People’s Republic of China
Funding
Ministry of Science and Technology of the People's Republic of China · Australian Government · Science and Technology Program of Suzhou
References (33)
Show source-provided references
1. 10.3322/caac.2165410.3322/caac.21654 ↗
2. 10.1056/NEJMoa171444810.1056/NEJMoa1714448 ↗
3. 10.1056/NEJMoa180100510.1056/NEJMoa1801005 ↗
4. 10.1016/S0140-6736(18)32487-510.1016/S0140-6736(18)32487-5 ↗
5. 10.1016/j.canlet.2020.12.02410.1016/j.canlet.2020.12.024 ↗
6. 10.1038/s41392-017-0004-310.1038/s41392-017-0004-3 ↗
7. 10.1021/acs.nanolett.8b0476310.1021/acs.nanolett.8b04763 ↗
8. 10.1126/science.aan370610.1126/science.aan3706 ↗
9. 10.1073/pnas.171442111510.1073/pnas.1714421115 ↗
10. 10.1016/j.addr.2015.10.01410.1016/j.addr.2015.10.014 ↗
11. 10.1039/C7CS00522A10.1039/C7CS00522A ↗
12. 10.1021/acs.accounts.8b0006010.1021/acs.accounts.8b00060 ↗
13. 10.1002/advs.20180051010.1002/advs.201800510 ↗
14. 10.1126/sciadv.abb469610.1126/sciadv.abb4696 ↗
15. 10.1038/s41467-018-03473-910.1038/s41467-018-03473-9 ↗
16. 10.1039/C9MH01197H10.1039/C9MH01197H ↗
17. 10.1002/adma.20130525610.1002/adma.201305256 ↗
18. 10.1038/s41551-018-0203-410.1038/s41551-018-0203-4 ↗
19. 10.1016/j.biomaterials.2019.04.02410.1016/j.biomaterials.2019.04.024 ↗
20. 10.1038/s41467-018-07197-810.1038/s41467-018-07197-8 ↗
21. 10.1021/acs.analchem.9b0369410.1021/acs.analchem.9b03694 ↗
22. 10.1039/C7SC05246D10.1039/C7SC05246D ↗
23. 10.1039/C5NR03092G10.1039/C5NR03092G ↗
24. 10.1002/adma.20140140210.1002/adma.201401402 ↗
25. 10.1021/acsnano.8b0390010.1021/acsnano.8b03900 ↗
26. 10.1039/C4CS00011K10.1039/C4CS00011K ↗
27. 10.1021/nn302633q10.1021/nn302633q ↗
28. 10.1002/ange.20120401810.1002/ange.201204018 ↗
29. 10.1021/acs.nanolett.9b0225310.1021/acs.nanolett.9b02253 ↗
30. 10.1002/anie.20060225110.1002/anie.200602251 ↗
31. 10.1002/adma.20120468310.1002/adma.201204683 ↗
32. 10.1021/acs.nanolett.7b0302110.1021/acs.nanolett.7b03021 ↗
33. 10.1016/j.bioactmat.2020.08.03410.1016/j.bioactmat.2020.08.034 ↗